07:00 , Oct 17, 2011 |  BioCentury  |  Emerging Company Profile

KalVista: Filling the VEGF void

KalVista Pharmaceuticals Ltd. believes its small molecule plasma kallikrein inhibitors will treat diabetic macular edema on par with VEGF inhibitors and will work in more patients. The biotech also hopes to offer injectable and oral...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

ASP-440 ophthalmic data

In a rat model of diabetes, ASP-440 for 4 weeks significantly reduced the excess rate of albumin leakage into the retina by >80% vs. vehicle-treated controls to levels not significantly different from that of...
07:00 , Oct 24, 2005 |  BC Week In Review  |  Company News

Ensemble Discovery, Fujitsu Ltd. deal

Fujitsu's BioSciences group licensed its BioMedCAChe suite of automated docking and molecular modeling software to Ensemble. Ensemble also received access to Fujitsu's ActiveSite module for designing small molecule inhibitors of protein targets. Financial terms were...
08:00 , Feb 28, 2005 |  BC Week In Review  |  Company News

NeurAxon, Fujitsu Ltd. deal

NeurAxon received a license to BioMedCAChe automated docking and molecular modeling software from Fujitsu's Fujitsu America BioSciences Group (Westwood, Mass.). The deal also includes Fujitsu's ActiveSite module for designing small molecule inhibitors of protein targets....